Clinical Trial: Safety, Tolerability, and Pharmacokinetic Study of ISIS ApoC-III Rx in Hypertriglyceridemia

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional

Official Title: A Randomized, Double-Blind, Placebo-Controlled, Dose Response, Phase 2 Study of ISIS 304801 Administered Subcutaneously to Patients With Severe or Uncontrolled Hypertriglyceridem

Brief Summary: The purpose of this study is to evaluate the dose/response pharmacodynamic effects of ISIS ApoC-III Rx vs. Placebo on fasting total apoC-III levels.

Detailed Summary:
Sponsor: Ionis Pharmaceuticals, Inc.

Current Primary Outcome: VLDL apoC-III [ Time Frame: 92 Days ]

The effect of treatment with ISIS ApoC-III Rx or Placebo on fasting total apoC-III levels.


Original Primary Outcome: VLDL apoC-III [ Time Frame: 92 Days ]

The effect of treatment with ISIS ApoC-III Rx or Placebo on VLDL ApoC-III levels.


Current Secondary Outcome:

Original Secondary Outcome:

Information By: Ionis Pharmaceuticals, Inc.

Dates:
Date Received: February 6, 2012
Date Started: February 2012
Date Completion:
Last Updated: June 14, 2016
Last Verified: June 2016